Native TEG |
Measures clot formation in the absence of a specific activator in either untreated whole blood or in citrated whole blood after recalcification. |
Rapid-TEG (rTEG) |
Tissue factor is used as the activator inducing clot formation via the extrinsic pathway. Compared with native TEG, rTEG gives a readout of clot characteristics within about 10 minutes. The corresponding RoTEM test is the EXTEM. |
Kaolin-TEG |
Phospholipid and kaolin are used to induce activation via the intrinsic pathway. The corresponding RoTEM test is the INTEM, which uses phospholipid and ellagic acid as activators. |
Heparinase treatment |
Simultaneous measurements can be performed comparing heparinase-treated blood with untreated blood to identify the effects of endogenous heparan sulfates, exogenous heparin, and heparinoids. The corresponding RoTEM assay is the HEPTEM. |
Platelet mapping |
Platelet mapping assesses platelet function via the cyclooxygenase and ADP/P2 signaling pathways. The decrement in MA can be measured in the presence of platelet antagonists such as acetylsalicylic acid, dipyridamole, and clopidogrel and compared with the untreated MA. |
Fibrin function testing |
The RoTEM FIBTEM test activates the extrinsic pathway in the presence of cytochalasin D, which is a cytoskeletal inhibitor of platelet activity. This test qualitatively assesses fibrinogen levels since the clot formation in this test is attributable to fibrin polymerization alone. |
Do you want to add Medilib to your home screen?